Erik Walldén

Affibody Medical AB provides biopharmaceuticals services. It develops Affibody, an antibody mimetic and Albumod, a technology that enhances the efficacy of biopharmaceuticals by extending their circulatory half-life through a strong binding to albumin. The company was founded by Karin Nord and Carl Erik Mathias Uhlén in 1998 and is headquartered in Stockholm, Sweden.

Healthinvest Partners AB (Healthinvest) is an alternative investment management firm headquartered in Stockholm, Sweden. The firm was founded by Anders Hallberg and Carl Bennet in 2006. They are owned by Atle Investment Management AB, which is a subsidiary of Bure Equity AB (STO: BURE). Healthinvest manages HealthInvest Alpha Fund – which is an actively managed global healthcare fund with a value-based approach, and HealthInvest Sustainable Healthcare – a global healthcare fund where the investment philosophy is characterized by medical progress and innovation with a strong focus on sustainability. In addition, the firm manages the fund Avanza Healthcare on behalf of Avanza.

SwedenBIO Service AB is a non-profit company that develops biotechnology, diagnostics, pharmaceuticals, and medical technology. It also offers counseling, education, opinion formation, and investigations. The company was founded in 2002 and is headquartered in Stockholm, Sweden.

Biacore International AB offers systems that generate data on the interactions between proteins and small molecule drug candidates. Its systems are used in pharmaceutical drug discovery, antibody characterization, proteomics, immunogenicity, biotherapeutic development and manufacture and life science research applications. The company serves research centers, pharmaceutical and biotechnology companies. Biacore International markets its products in the United States, Europe, Japan and Australia. The company was founded in 1984 and is headquartered in Uppsala, Sweden

Affibody AB conducts research and development services within biotechnology. It markets and sells licensed products and research findings to the pharmaceutical industry. The company was founded by Karin Nord in 1998 and is headquartered in Stockholm, Sweden.

Exiqon A/S engages in the development of solutions for ribonucleic acid research and analysis through its Locked Nucleic Acid proprietary technology. Its products and services are used by researchers in academia, biotech, and pharmaceutical companies around the world to make discoveries about the correlation between gene activity and the development of disease. The company was founded by Mikael Ørum, Henrik Ørum and Troels Koch on November 1, 1995 and is headquartered in Copenhagen, Denmark.

Part of CellSeed, Inc., Cellseed Sweden AB performs clinical trials. Setsuko Hashimoto has been the CEO of the Swedish company since 2015.

Beactica Therapeutics AB operates as a drug discovery company, utilizing its proprietary methodologies to evaluate the interactions of molecules in order to generate novel therapeutics. The firm's services include fragment-based lead generation, kinetic and mechanistic characterization of inhibitors, extended rate analysis, competition analysis, and antibody interaction analysis. The company was founded by Per K?llblad and Ulla Helena Danielson in 2006 and is headquartered in Uppsala, Sweden.

SymCel AB develops and markets analytical instrumentations for cell biological research and development. Its products include calScreener, calPlate System, and calView date collection and analysis software. The company was founded by Dan Rolf Stefan Hallen and Bertil Ingemar Wadso in 2004 and is headquartered in Spanga, Sweden.

Lumicks BV is a Dutch life science tools company that develops equipment for dynamic single-molecule and cell avidity analysis. The company is based in Amsterdam, NL, and has subsidiaries in the Netherlands and the United States. The company's tools allow researchers to analyze complex biological processes in real-time by applying and measuring forces around biological interactions. Lumicks' C-Trap® optical tweezers and fluorescence & label-free microscopy, and Z-Movi® cell avidity analyzer are used to measure and select immune cells based on their real-time interactions with target cells. Lumicks was founded in 2014 by Olivier Heyning and Andrea Candelli, with Olivier Heyning serving as the CEO since then.